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Abstract
Background: To assess the direct cost of relapse and the predictors of relapse during the treatment of patients
with schizophrenia in the United States.
Methods: Data were drawn from a prospective, observational, noninterventional study of schizophrenia in the
United States (US-SCAP) conducted between 7/1997 and 9/2003. Patients with and without relapse in the prior 6
months were compared on total direct mental health costs and cost components in the following year using
propensity score matching method. Baseline predictors of subsequent relapse were also assessed.
Results: Of 1,557 participants with eligible data, 310 (20%) relapsed during the 6 months prior to the 1-year study
period. Costs for patients with prior relapse were about 3 times the costs for patients without prior relapse. Relapse
was associated with higher costs for inpatient services as well as for outpatient services and medication. Patients
with prior relapse were younger and had onset of illness at earlier ages, poorer medication adherence, more
severe symptoms, a higher prevalence of substance use disorder, and worse functional status. Inpatient costs for
patients with a relapse during both the prior 6 months and the follow-up year were 5 times the costs for patients
with relapse during the follow-up year only. Prior relapse was a robust predictor of subsequent relapse, above and
beyond information about patients’ functioning and symptom levels.
Conclusions: Despite the historical decline in utilization of psychiatric inpatient services, relapse remains an
important predictor of subsequent relapse and treatment costs for persons with schizophrenia.
Background
Schizophrenia is a severe and chronic mental illness
characterized by recurring relapses that may require
inpatient hospitalization. Costs associated with treat-
ment received consequent to relapse may account for
the largest share of treatment costs in schizophrenia
[1-4], which is one of the most expensive to treat psy-
chiatric conditions [5]. Socio-demographic and clinical
factors associated with relapse have been examined in
previous research studies [2-4,6-9]. However, except for
results from 1 published study [1], information about
potential predictors of relapse and its associated treat-
ment costs in the United Stated are scarce.
Information about the cost of relapse in schizophrenia
and the predictors of relapse is of interest to clinicians,
payers, and other health care decision makers. Intensive
outpatient service interventions, such as assertive com-
munity treatment, partial hospitalization programs, and
programs for persons with co-occurring addictive disor-
ders, which are designed for persons at risk of acute
relapse, could help prevent or minimize relapses and
attendant health care costs. However, intensive outpati-
ent interventions cost too much to be offered to all
patients with schizophrenia who might benefit from
them. As a result, accurate prediction of risk of relapse
is critical to identifying persons who may need these
intensive outpatient interventions.
In essentially the only study of the costs of relapse for
persons treated for schizophrenia in the United States,
Weiden and Olfson estimated that, on a national level,
almost $2 billion is spent annually for hospital readmis-
sions of patients with schizophrenia [1]. That study,
though based on a national sample, was based on a
cross-sectional database that contained limited
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over time. The data used in the present study were from
a longitudinal observational study of persons treated for
schizophrenia in usual-care settings in the United States.
T h ep u r p o s eo ft h es t u d yw a st oe s t i m a t et h ed i r e c t
annual mental health costs of relapse and its cost com-
ponents, to identify predictors of relapse, and to clarify
the role of recent, prior relapse on subsequent costs. It
was hypothesized that patients with prior relapse will
incur significantly higher total direct mental health cost
in the following year than patients without prior relapse
and that in addition to higher inpatient hospitalization
cost they will incur significantly higher cost of outpati-
ent services. We also hypothesized that patients with
both prior and subsequent relapse will be the costliest
and that prior relapse will be a significant predictor of
subsequent relapse along with other distinct patient
characteristics such as substance use and poor medica-
tion adherence.
Methods
Data source
Data were used from the US Schizophrenia Care and
Assessment Program (US-SCAP), a large (N = 2,327) 3-
year prospective, observational, noninterventional study
of schizophrenia treatment in usual-care settings in the
United States conducted between July 1997 and Septem-
ber 2003. Participants were recruited from diverse geo-
graphic areas, including the Northeast, Southwest, Mid-
Atlantic, and West. The 6 participating regional sites
represented large systems of care, including community
mental health centers, university health care systems,
community and state hospitals, and the Department of
Veterans Affairs Health Services. Institutional Review
Board approval was obtained, and informed consent was
received from all participants.
Participants were ages 18 or older and had been diag-
nosed with schizophrenia, schizoaffective, or schizophre-
niform disorder based on Diagnostic and Statistical
Manual, Version 4 criteria. Participants were excluded if
they were unable to provide informed consent or had
participated in a clinical drug trial within 30 days prior
to enrollment. Approximately 400 patients enrolled at
each of the 6 study sites. Enrollment was not contingent
upon participants having been treated with any medica-
tion and was independent of concurrent psychiatric or
medical conditions, use of concomitant medications, or
substance use. Patients could stay on medications
received prior to enrollment, and decisions about medi-
cation changes, if any, were made by the physicians and
their patients. Further details about US-SCAP have been
reported elsewhere [10,11].
Analytical sample
Of 2,327 patients in the US-SCAP, 1,817 (78%) com-
pleted a 1-year follow-up interview. Of these 1,817
patients, the present analysis included only participants
for whom complete mental health resource utilization
data were available for an entire year (N = 1,557 or
85.7%). If more than 1 year of complete resource use
information was available for a given patient, data from
the earliest year were used. The first year of patients’
participation in the study was often the study year.
In addition to comparing patients with and without
prior relapse on baseline characteristics and on mental
health costs, the impact of prior relapse on subsequent
relapse (within the following year) was assessed. This
resulted in 4 mutually exclusive groups: 1) patients who
relapsed during both time periods (prior Relapse and
subsequent Relapse, designated “RR”); 2) patients with
No prior relapse but with subsequent Relapse (desig-
nated “NR”); 3) patients with prior Relapse but with No
subsequent relapse (designated “RN”); and 4) patients
who did not relapse during either time period (No prior
relapse and No subsequent relapse, designated “NN”).
Measures
Relapse was defined as having any of the following: psy-
chiatric hospitalization, use of emergency services, use
of a crisis bed, or a suicide attempt. These relapse para-
meters, with the exception of suicide attempt, were
based on information systematically abstracted from
patients’ medical records every 6 months, using an
abstraction form developed for the study. Suicide
attempts, for the previous 1-month period, were
reported by the patients on the SCAP-Health Question-
naire (SCAP-HQ), a validated measure developed for
the study [12].
Standard psychiatric measures were used to assess
participant sociodemographic, clinical, and functional
status at baseline. A structured interview was used to
identify sociodemographic characteristics. Level of
symptom severity was assessed annually with the Posi-
tive and Negative Syndrome Scale (PANSS) [13] and the
Montgomery-Åsberg Depression Rating Scale (MADRS)
[14]. Levels of functioning in various domains were
a s s e s s e dw i t ht h eS C A P - H Q ,w h i c hp r o v i d e di n f o r m a -
tion on suicide attempts, violent behaviors, medication
adherence, drug and alcoho lu s ef o rt h ep r e v i o u s
month, and arrests in the previous 6 months. Mental
and physical levels of functioning were assessed with the
12-Item Short Form Health Survey (SF-12) [15].
Patient-reported medication adherence was assessed
with SCAP-HQ on a 5-point scale. Participants who
reported they “never missed” taking their medication or
“missed only a couple of times but basically took all
medicine” were considered adherent, whereas all others
("took at least half,”“ took less than half,” or “stopped
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addition to patient-reported adherence, medication
adherence in the 6 months before the study year was
measured by the Medication Possession Ratio (MPR)
[2,6]. Using prescription information in patient medical
records, the MPR was calculated as the proportion of
days with any antipsychotic medication. An MPR value
of at least .80 is considered being adherent [6]. Prior
research found high correspondence between antipsy-
chotic prescription and their pharmacy fill in this popu-
lation [4], and the prescription-based MPR used in this
analysis has previously provided results highly consistent
with research using pharmacy fill-based MPR [10].
Resource utilization and cost
Mental health resource utilization information for each
participant was abstracted at baseline and every 6
months thereafter by trained examiners who used a
medical record abstraction form developed for this
study. At these time points, participants were also quer-
ied about treatment received outside their usual health
care site, and study personnel obtained medical records
from these treatment centers as needed. Total 1-year
direct mental health costs included the following cost
components: costs of medications (antipsychotics, other
psychotropics, such as mood stabilizers, anticholinergics,
antidepressants, antianxiety, and sleep agents), psychia-
tric hospitalizations, day treatment, emergency services,
psychosocial group therapy, medication management,
individual therapy, and ACT/case management. Consis-
tent with prior antipsychotic drug cost research [16,17],
the costs of atypical antipsychotic medications were
based on average wholesale prices discounted by 15%,
reflecting the customary discount level in the United
States. Costs of psychiatric hospitalization were based
on daily per diem costs at each site. To help address
variations in resource utilization types, durations, and
costs across study sites, the costs of mental health ser-
vices other than psychiatric hospitalizations, were based
on their relative value units developed from resource
utilization and cost data available from the management
information systems at each site [18,19]. Direct cost
data were not available for the 6-month pre-study per-
iod, but data on relapse, including number of psychiatric
hospitalizations and length of stay (LOS) were available.
Statistical analysis
Initial statistical group comparisons assessed patients
who relapsed during the prior 6 months compared with
patients who did not (RR and RN versus NR and NN).
Following this, pairwise comparisons among the 4
groups based on prior and subsequent relapse status
(NN, NR, RR, and RN) were conducted. Group compari-
sons were performed using t tests for continuous vari-
ables and Mantel-Haenszel c
2 tests for categorical
variables. Average total direct mental health costs and
cost components were assessed during the study year
and were compared between patients who relapsed (in
the 6 months preceding the 1-year follow-up) and those
who did not using propensity score adjusted bootstrap
resampling. Propensity score stratification [20] was used
to adjust for potential confounding factors not attributa-
ble to relapse status. A priori covariates for calculating
the logit score with this method were age; gender; race/
ethnicity; illness duration; insurance status; a diagnosis
of a schizoaffective disorder, comorbid substance use,
personality disorder, or mental retardation; enrollment
site; a binary indicator for psychiatric hospitalization at
the time of enrollment into the US-SCAP study; and
time elapsed between US-SCAP enrollment and the
start date of each patient’s study year. As a sensitivity
analysis, the a priori propensity score model was modi-
fied to include all baseline covariates for which statisti-
cally significant group imbalance was found. The
bootstrap resampling approach (1,000 iterations) was
used to provide a nonparametric approach due to the
skewness of the cost data.
To determine predictors of relapse during the 1-year
study period, a stepwise logistic regression analyses was
conducted for (1) all patients, (2) patients with prior
relapse, and (3) patients without prior relapse.
Results
Patients with versus without prior relapse
Of 1,557 participants eligible for analyses, 310 (20%)
relapsed in the 6 months prior to the study period, and
1,247 (80%) did not. As shown in Additional file 1,
patients with prior relapse were significantly younger,
with earlier age at illness onset, more severe schizophre-
nia symptoms and depressive symptoms, higher rates of
psychiatric hospitalization in the year prior to enroll-
ment in the study, substance use disorder, arrests, and
victimization by others. They also had significantly
poorer levels of mental health and were less likely to be
adherent with medication (per self-report and MPR). Of
the 310 patients with prior relapse, 281 (91%) had a psy-
chiatric hospitalization, 41 (13%) used emergency ser-
vices or crisis beds, and 20 (6%) reported suicide
attempts (numbers exceed 100% because some patients
met more than 1 relapse criterion). Most patients (258
of 310, or 83%) met 1 of these 4 criteria for relapse; 31
(10%) met 2; 21 (7%) met 3; and no participant met all
4. Only 1% of the patients (22 of 1557) were inpatients
at the start of their 1-year study period.
Compared to patients who did not experience prior
relapse, patients with prior relapse incurred significantly
higher total annual direct mental health care costs dur-
ing the 1-year study period, which were nearly 3 times
higher for the relapsed ($33,187 ± $47,616) compared
with those who did not ($11,771 ± $10,611, p < .01).
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psychiatric hospitalization and emergency services costs,
they also incurred significantly higher costs for medica-
tions and various outpatient services, including medica-
tion management, day treatment, individual therapy, and
ACT/case management. Results were essentially
unchanged when the a priori propensity score model
was modified to include baseline covariates for which
statistically significant group difference was found.
Furthermore, to help assess whether knowledge about
previous relapse improves the ability to predict subse-
quent treatment costs over and above potential associa-
tions with patients’ current level of functioning and
symptomatology, we have conducted a sensitivity analy-
sis. This analysis compared the total cost and cost com-
ponents between patients with versus without relapse
while adjusting for clinical and functional status as mea-
sured by the PANSS, MADRS, and SF12 (physical com-
ponent score and mental component score) using
propensity score estimation. Results of this sensitivity
analysis were essentially the same, except that the origi-
nal significant group differences on medication cost
(with significantly higher medication cost for patients
with prior relapse) became statistically non-significant.
Findings support, therefore, that knowledge about pre-
vious relapse improves the ability to predict subsequent
treatment costs above and beyond information about
patients’ functioning and symptom levels.
Comparisons between groups by prior and subsequent
relapse status
Among the 1,557 participants with eligible data, 1,078
( 6 9 % )d i dn o tr e l a p s ei nt h ep r i o r6m o n t h so rd u r i n g
the subsequent 1-year study period (NN group), 157
(10%) experienced relapse during both periods (RR
group), 169 participants (11%) did not have a prior
relapse but relapsed during the 1-year study period (NR
group), and the remaining 153 (10%) experienced prior
relapse but did not relapse during the 1-year study per-
iod (RN group). These findings indicate that among the
non-relapsed in the 1-year follow-up period, 87.6%
(1078 of 1231) were correctly identified as non-relapsed
based on their prior 6-month status (relapsed or not).
This high specificity level was accompanied by moderate
sensitivity (48.2%), high negative predictive value
(86.4%), moderate positive predictive value (50.6%), and
a high overall accuracy level (79.3%).
As shown in Additional file 2, significant differences
were observed between these 4 groups on baseline char-
acteristics and cost parameters. Compared to patients
without prior relapse who relapsed in the subsequent
year (NR), the patients with both prior and subsequent
relapse (RR) were significantly younger, had a psychia-
tric hospitalization in the year prior to study enrollment,
had more severe symptoms on the PANSS and MADRS,
had poorer physical health functioning, and were more
likely to be nonadherent per self-report and per medica-
tion records (MPR). Compared to the NR group, the
group without prior or subsequent relapse (NN) was
older, less likely to have comorbid substance-use disor-
der, had a psychiatric hospitalization in the year prior to
study enrollment, had better mental and physical health
functioning, and had less severe depressive symptoms.
Compared to the NR group, patients with prior relapse
but without subsequent relapse (RN) were younger, less
likely to have health insurance, had a higher hospitaliza-
tion rate in the year prior to study enrollment, and had
better physical health functioning. Patients without prior
or subsequent relapse (NN group) differed from those
with both prior and subsequent relapse (RR group) on
baseline variables associated with prior relapse, as noted
earlier.
The 4 patient groups were also compared on total cost
and cost components for the subsequent year (Addi-
tional file 2). As expected, the RR group was the cost-
liest and was about 5 times more costly than the group
who did not relapse (NN). Interestingly, the RR group
was 2.4 times more costly than the NR group, although
both groups relapsed during the 1-year study period,
highlighting the impact of prior relapse on the total
cost. In addition, the cost for the RN group was 1.5
times that of the NN group, demonstrating again the
economic impact of prior relapse even when no subse-
quent relapse took place. Costs were driven primarily by
psychiatric hospitalization and antipsychotic medica-
tions; the mean hospitalization cost for the RR group
was almost 5 times that for the NR group ($38,104 vs.
$7,786, p < .001). To better understand the drivers of
the differences between the NR and RR groups on hos-
pitalization costs during the 1-year study period, this
analysis further compared them on hospitalization para-
meters. The RR group was found to have a significantly
higher average LOS per psychiatric admission compared
to the NR group (51.24 ± 101.41 vs. 9.84 ± 20.94 days,
p < .001) and significantly more psychiatric hospitaliza-
tions (1.46 ± 1.22 vs. 0.99 ± 0.84, p < .001).
Predictors of relapse
The predictors of relapse in the 1-year study for all
patients and by prior relapse status are presented in
Additional file 3. Overall (Additional file 3A), the pre-
dictors of subsequent relapse included presence of prior
relapse, having health insurance, being medication non-
adherent, younger at illness onset, and poorer function-
ing level. Among patients with prior relapse (RN vs. RR
groups, Additional file 3B), the predictors were more
severe schizophrenia symptoms per PANSS and a higher
number of psychiatric hospital admissions in the prior
year. Among patients without prior relapse (NN vs. NR,
Additional file 3C), the predictors of subsequent relapse
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study enrollment, earlier age of illness onset, and poorer
level of functioning.
Discussion
Although prior relapse has long been known to predict
future relapse in the study of schizophrenia, this study
provides new and useful information about the cost of
relapse and its cost components in the United States,
the predictors of relapse, and the important role of pre-
vious relapse, above and beyond information about
patients’ functioning and symptom levels. Current find-
ings demonstrate that the annual mental health cost of
relapsed patients is about 2 to 5 times higher than for
non-relapsed patients, depending on whether the
patients had relapsed in the 6 months prior to the 1-
year study period. Prior relapse was found to be a strong
predictor of subsequent relapse (overall accuracy 79%),
s h o w i n gt h a tm o s tp a t i e n t sw h od i dn o tr e l a p s ei nt h e
1-year study period (88%) were correctly identified as
non-relapsed based on their previous 6-month non-
relapse status (high specificity). Moreover, when asses-
sing the costs of patients who relapsed during the 1-
year period, those with prior relapse were about 2.8
times more costly. The cost differential was primarily
driven by a higher number of hospitalizations and by
longer hospital stay per admission. Importantly, the
expected higher acute care costs of relapsed patients
were accompanied by higher costs for various outpatient
services and medication, suggesting that the cost of
relapse is not confined to the cost of hospitalizations
and emergency services as payers tend to believe, as
relapse is also linked to more intense and thus more
costly medication management, day treatment, indivi-
dual therapy, and ACT/case management.
Consistent with prior research [1-3,6,9,21,22], the cur-
rent analysis also found relapsed patients to have a
more complex illness profile, which is not only asso-
ciated with more severe symptomatology but also sub-
stance use, legal involvement, lower level of functioning,
and poorer medication adherence. Furthermore, this
study identified a small set of variables that help predict
subsequent relapse in the usual treatment of schizophre-
nia, demonstrating the predictive value of prior relapse
as a robust marker, along with prior medication nonad-
herence, younger age at illness onset, having health
insurance, and poorer level of functioning. The use of
these predictors in clinical practice may help improve
allocation of resources, such as active case management
and adherence interventions, since these programs aim
to prevent relapse and hospitalization.
Current findings may also be of value for modeling
the cost-effectiveness of treatment for schizophrenia and
may also be of interest to payers and other health care
decision makers, especially those involved in developing
Medicare capitation models for patients with chronic
conditions such as schizophrenia. Using a robust and
simple clinical marker such as recent relapse may help
improve the accuracy of Medicare risk adjustment mod-
els. This information may also be applicable to risk
adjustments of premiums under Medicare Part D plans
because drug expenditures in the previous year generally
had been found to be strongly predictive of current-year
drug expenditures for individuals [23,24]. Policy analysts
have suggested that this expenditure pattern between
prior and current years should be reflected in risk-
adjustment formulae [25], and specifically in Medicare
Part D [26].
This study has a number of strengths, including the
breadth of its clinical and economic measures and the
diversity of the patient population across geographies
and health care systems, suggesting high generalizability
of the findings. The study also has limitations. First is
the potential for selection bias. Although propensity
score matching was used to adjust for potential selection
bias, such methods cannot account for all potentially
confounding factors (i.e., unmeasured variables). For
example, patients who were hospitalized continuously
during the 1-year study period might have contributed
disproportionately to overall costs. Accordingly, an addi-
tional sensitivity analysis was performed in which 13
such patients were excluded; results were highly consis-
tent with the original findings (e.g., total cost was 2.2
times higher for patients with versus without prior
relapse rather than 2.8 times higher). This study also
assessed the potential impact of excluding patients from
the analysis due to their lacking complete resource utili-
zation data. The excluded patients differed significantly
from the included patients on variables shown to be
associated with relapse (e.g., younger age, prior hospita-
lizations, poorer adherence, and more severe symptoms),
suggesting that the overall rate of relapse has likely been
underestimated.
Second, the costs in this study only reflected direct
mental health cost and not total health care costs
because the US-SCAP study did not collect data on
non-psychiatric resource utilization or indirect costs.
Third, the study did not have complete mental health
resources information for all patients across the 3-year
study, thus curtailing the ability to assess change in
costs over time. Fourth, the study did not assess the rea-
son for patients’ psychiatric hospitalization; thus there is
a possibility that some hospitalizations may not have
been directly linked to exacerbation of schizophrenia.
And lastly, the results of this study may not be general-
izable to patients with schizophrenia whose treatment is
covered by private payers because public payers covered
almost all US-SCAP participants [10,27].
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Relapse of patients with schizophrenia is associated with
substantial direct mental health costs that extend
beyond the cost of hospitalization to other costly outpa-
tient services and medication costs. Findings highlight
the economic impact of relapse and the importance of
prior relapse as a predictor of subsequent relapse for
clinicians and other health care decision makers. Future
research is needed to evaluate the longer-term effects
on patient outcomes and health care costs of targeting
different interventions to patients at high risk of relapse.
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